Late-onset neutropenia (LON) is emerging as a common adverse effect to rituximab therapy owing to widespread use of this drug in the treatment of B-cell lymphomas and autoimmune diseases. However, the ...

Drug-induced neutropenia and agranulocytosis represent serious adverse haematological conditions arising from the administration of a variety of therapeutic agents. These conditions involve a marked ...

Objective: Patients receiving cancer treatments commonly experience haematological adverse effects (AEs) related to chemotherapy or molecularly targeted therapies, which may be associated with high ...

FDA approves Filkri, a biosimilar that helps reduce infection risk and speed white blood cell recovery during chemotherapy and other treatments. The U.S. Food and Drug Administration (FDA) has ...

Poster #1654 highlights clinically meaningful and durable increases in circulating neutrophils observed with mavorixafor treatment +/- G-CSF over 6-month study Poster #1669 highlights findings that ...

BOSTON, Nov. 13, 2024 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced positive new ...

X4 Pharmaceuticals announced the acceptance of two abstracts for presentation at the upcoming European Hematology Association Congress regarding the positive results from their Phase 2 trial of ...